Department of Medical Oncology, Nanjing General Hospital of Nanjing Military Command, PLA, Nanjing 210002, China.
Lung Cancer. 2009 Nov;66(2):237-44. doi: 10.1016/j.lungcan.2009.02.001. Epub 2009 Mar 3.
Eukaryotic initiation factor 4E (eIF4E), an important regulator of translation, plays important roles in tumor transformation, progression and metastasis. However, the clinical significance of eIF4E expression in lung adenocarcinoma (AdC) remains unclear. The aim of this study was to explore the expression of eIF4E gene in lung adenocarcinoma cell lines and tissues, and to investigate its relationship with clinical characteristics and prognosis of patients with lung adenocarcinoma in combination with p53 status.
Semi-quantitative RT-PCR and Western blotting assays were performed to detect the expression of eIF4E mRNA and protein in normal human lung epithelial cell line, immortalized lung epithelial cell line and lung adenocarcinoma cell lines. Additionally, the expression of eIF4E gene was also detected in 32 cases of lung adenocarcinoma tissues, tumor adjacent tissues and tumor surrounding normal tissues by the same methods. Moreover, expression of eIF4E and the status of p53 in specimens from 76 patients with lung adenocarcinoma were examined by immunohistochemical staining. Correlations between eIF4E expression and clinicopathological features, and the effect of eIF4E on prognosis of patients with lung adenocarcinoma were evaluated by statistical analysis.
The levels of eIF4E mRNA and protein expression were higher in lung adenocarcinoma cell lines and in telomerase-immortalized lung epithelial cell line than in the normal lung epithelial cell line. The expression of eIF4E gene showed statistical difference between tumor tissues, tumor adjacent tissues and tumor surrounding normal tissues (P<0.05). Moreover, the higher levels of eIF4E expression were correlated with poorer differentiation (P=0.012), higher pathological stage (P<0.0001) and clinical stage (P=0.002), a higher incidence of hematogenous metastasis (P=0.007) and cancer-related death (P=0.036). The 5-year survival rate of patients with higher eIF4E expression was significantly lower than that of patients with lower eIF4E expression (P=0.0045). Furthermore, in a multivariate analysis by Cox regression model, high eIF4E expression was confirmed to be an independent prognostic factor (HR: 2.258; unfavorable, P=0.0056), while lymph node (HR: 2.033; unfavorable, P=0.0440) and hematogenous metastasis (HR: 3.489; unfavorable, P<0.0001) were also significant prognostic factors.
High eIF4E expression was correlated with poorer overall survival in lung adenocarcinoma patients. eIF4E might be a better clinical marker predicting the prognosis for lung adenocarcinoma patients in combination with p53 status.
真核起始因子 4E(eIF4E)是翻译的重要调节因子,在肿瘤转化、进展和转移中发挥重要作用。然而,eIF4E 表达在肺腺癌(AdC)中的临床意义尚不清楚。本研究旨在探讨 eIF4E 基因在肺腺癌细胞系和组织中的表达,并结合 p53 状态,探讨其与肺腺癌患者临床特征和预后的关系。
采用半定量 RT-PCR 和 Western blot 检测正常肺上皮细胞系、永生化肺上皮细胞系和肺腺癌细胞系中 eIF4E mRNA 和蛋白的表达。采用相同方法检测 32 例肺腺癌组织、癌旁组织和肿瘤周围正常组织中 eIF4E 基因的表达。采用免疫组织化学染色法检测 76 例肺腺癌患者标本中 eIF4E 和 p53 的表达。通过统计学分析评估 eIF4E 表达与临床病理特征的相关性及其对肺腺癌患者预后的影响。
肺腺癌细胞系和端粒酶永生化肺上皮细胞系中 eIF4E mRNA 和蛋白的表达水平均高于正常肺上皮细胞系。eIF4E 基因在肿瘤组织、癌旁组织和肿瘤周围正常组织中的表达存在统计学差异(P<0.05)。此外,eIF4E 表达水平较高与分化程度较差(P=0.012)、病理分期较高(P<0.0001)、临床分期较高(P=0.002)、血行转移发生率较高(P=0.007)和癌症相关死亡率较高(P=0.036)相关。eIF4E 表达较高的患者 5 年生存率明显低于 eIF4E 表达较低的患者(P=0.0045)。此外,通过 Cox 回归模型多因素分析,高 eIF4E 表达被确认为独立预后因素(HR:2.258;不利,P=0.0056),而淋巴结(HR:2.033;不利,P=0.0440)和血行转移(HR:3.489;不利,P<0.0001)也是显著的预后因素。
高 eIF4E 表达与肺腺癌患者总体生存率降低相关。eIF4E 可能是结合 p53 状态预测肺腺癌患者预后的更好的临床标志物。